Recently published Johns Hopkins Medicine research shows that older immunocompromised people have a weaker response to respiratory syncytial virus (RSV) vaccinations.
However, study lead author Andrew Karaba, M.D., Ph.D., and study senior author William Werbel, M.D., Ph.D. say, “this study does not suggest RSV vaccines will not reduce RSV disease in people who are immunocompromised,” according to a Johns Hopkins release.
The study observed 38 immunocompromised male and female patients aged 64-72 who “received either the RSVPreF3-AS01 (also known as Arexvy) or RSVpreF (also known as Abrysvo) vaccine.”
The Johns Hopkins release quotes William Werbel, M.D., Ph.D., the study’s senior author, “‘When we compared the antibody responses between those study participants who received Arexvy with those who got Abrysvo, we found that the group receiving the adjuvanted vaccine tended to have higher levels of RSV-neutralizing, anti-pre-fusion F antibodies,” says Werbel. “So, adjuvant-enhanced vaccines as a means of improving immune response in people who are immunocompromised merits further investigation in larger, more comprehensive studies.”
